Traduction de «glycogénose de type ii » (Français → Anglais) :

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and t ...[+++]reatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) how is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

(Return tabled) Question No. 4 Hon. Irwin Cotler: With regard to international treaties and conventions dealing in whole or in part with human rights and with Canada’s international obligations in this regard: (a) does the government have any formal or informal procedures for regular review of those international human rights treaties that Canada has not yet signed, ratified, or otherwise accepted; (b) does the government have any formal or informal guidelines according to which it determines whether the specific obligations contained in a treaty or other international undertaking conflicts with the Constitution Act, 1867, and if so where can these guidelines be accessed; (c) do the guidelines referred to in (b) specify the standard accor ...[+++]ding to which the government determines if any obligation contained in a treaty or other international undertaking violates any section of the Constitution Act, 1867; (d) has the government engaged in any review of its obligations under the Convention on the Elimination of Racial Discrimination (CERD); (e) does the government have any formal or informal guidelines according to which it determines whether the specific obligations contained in a treaty or other international undertaking require implementing legislation in order for Canada to be able to ratify or otherwise accept it, and if so where can these guidelines be accessed; (f) does the government have a position as to whether international agreements that establish a complaints mechanism or communications procedure for enforcement of the rights and obligations contained therein are necessarily unconstitutional; (g) does the government have a policy as to whether Canada will accept such agreements referred to in (f); (h) does the government undergo review of proposed international human rights agreements that would establish such a mechanism or procedure referred to in (f) on a case by case basis, (i) who is involved in this review, (ii) are the provinces and other inte ...

(Return tabled) Question No. 20 Mr. Alex Atamanenko: With regard to the horse slaughter industry in Canada: (a) what was the reason for the temporary halt, initiated by European Union (EU) officials, to horse meat imports from Canada on October 12, 2012; (b) has Canada participated in talks with EU officials regarding the safety of horse meat from Canada since that time, (i) if so, what topics were discussed, (ii) what conclusions were reached; (c) what restrictions effective in 2013 will be imposed upon the Canadian horse meat industry by the EU, (i) what is the anticipated impact of these restrictions on the frequency and ...[+++]type of drug residue testing on horse meat in Canada as well as on the data required on Equine Information Documents (EIDs), (ii) will the restrictions on prohibited/non-permitted drugs be further tightened; (d) is there any oversight by the Canadian Food Inspection Agency (CFIA) on transport drivers and horse meat dealers listed on EIDs as current owners to check for a history of violations of the United States Department of Agriculture, Ministry of Transport, or CFIA transport regulations, (i) does the CFIA enhance its scrutiny of such violators or conduct follow-up investigations on those who have been flagged for violations, (ii) is this information shared with any other inter-connected government agency either in Canada or in the United States; (e) how often do CFIA inspectors do a visual inspection of the transports that arrive at the slaughter plants to ensure that the horses have been transported safely; (f) how many transport violations concerning horse slaughter transportation have been issued to transport drivers within the last five years, (i) how many warnings of violations have been issued, (ii) if the warnings have been ignored, how does the CFIA restrict or prohibit those transport drivers from conducting business in Canada; (g) how often does the CFIA conduct inspections of feedlots and how many warnings or violations were ...

(18) The Commission should be empowered to adopt an implementing act in accordance with Article 291 of the Treaty in order to lay down uniform conditions for the implementation of this Regulation with regard to the list of information to be provided in applying for type-approval, type-approval procedures, templates for manufacturers’ additional plates, EU type-approval certificates, list of type-approvals issued, numbering system for EU type-approvals, and procedures to ensure conformity of production.

There are 7 immunological varieties of the FMD virus: 3 classic Euro-Asiatic types (types O, A and C) and 4 exotic types which affect only hot countries and originate in Southern Africa (SAT1, SAT2, SAT3) or Asia (ASIA 1) .

These medical crises have a preventable cause, that is type II diabetes. What are the government's plans for preventive measures which will reduce the negative effects of type II diabetes among First Nation populations?